Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivacaftor in CF with 3849+10KB C->T or D1152H mutations
NCT03068312Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Change in Lung Clearance Index 2.5 at 8 weeks. Started Jul 2017; status: completed.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03068312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03068312.